GLP-1s Are Driving Cost. Follow-Through Determines Outcomes.

Health plans and PBMs are bending the medical cost trend by fixing what happens next.

Rising costs aren't the problem. They're the result of unmanaged follow-through.

Adherence breaks → risk progresses → cost trend compounds. 

Upgrading individual parts won't fix an engine that isn't built to work as a system.

The shift happening now: Health plans and PBMs are treating GLP-1 and chronic condition management as a coordinated system - aligning pharmacy, behavior, provider, and clinical support to control trend and improve outcomes at scale.

Health plans and PBMs aren’t lacking tools, data, or programs. In fact, most organizations today have more visibility and more resources than ever before. Predictive models identify rising risk earlier. Pharmacy strategies are in place. Chronic condition programs are deployed. Engagement platforms are active.

On paper, everything is working.

And yet, cost trend continues to rise.

This disconnect isn’t coming from a lack of effort or investment. It’s coming from something much more fundamental: what happens after the initial decision is made.

The real gap isn’t access. It’s follow-through.

Across most populations, the pattern is familiar. A member is identified as high risk. A medication is prescribed. A program is recommended. Support is technically available. But what follows is inconsistent.

Adherence drops as complexity increases. Members disengage when support isn’t continuous. Care plans aren’t reinforced in daily behavior. Progress stalls, not because the right actions weren’t identified, but because they weren’t sustained.

Nothing breaks all at once. It simply doesn’t hold.

This is where cost trend is created - not at the point of diagnosis, not at the point of prescription, but in the gap between intention and execution.

GLP-1s didn’t create this problem. They made it visible.

The rapid growth of GLP-1 utilization has brought new urgency to an existing issue. Coverage has expanded, adoption is high, and these therapies are now central to many chronic condition strategies.

But outcomes remain inconsistent.

That’s because GLP-1 success isn’t determined at the moment of approval. It depends on everything that happens afterward: adherence over time, titration management, side-effect navigation, and behavior change aligned to treatment goals.

Without sustained, coordinated support, even the most promising therapies fail to deliver consistent results. High-cost populations remain unstable, and costs continue to compound.

What GLP-1s have exposed is not a medication problem. It’s a system problem.

More solutions aren’t solving it

In response, many organizations have added more support. Another condition program. Another engagement tool. Another vendor to address a specific gap.

Individually, these solutions often perform well. But collectively, they introduce fragmentation.

Engagement efforts operate separately from clinical care. Pharmacy strategies are not reinforced through daily behavior. Support is episodic rather than continuous. Data exists, but it doesn’t consistently translate into action.

Adding more pieces doesn’t resolve this. It increases complexity.

Upgrading individual parts doesn’t fix an engine that isn’t designed to work as a system.

The shift from solutions to systems

Leading health plans and PBMs are starting to approach this differently. Instead of asking what else needs to be added, they’re asking how everything currently in place can work together.

This shift from solutions to systems is where meaningful change begins.

A system connects risk identification to clear, personalized next steps. It aligns behavior with pharmacy and clinical strategy so that treatment plans are reinforced, not left to chance. It extends support beyond the point of care, recognizing that outcomes are shaped between visits, not just during them. And it measures success based on what actually matters: adherence, clinical outcomes, and population stability.

When these elements operate as one, follow-through becomes consistent. And when follow-through becomes consistent, outcomes improve.

From fragmented activity to measurable outcomes

When behavior, pharmacy, and clinical strategy are aligned, the impact is tangible. Members stay engaged longer. Adherence improves. Risk stabilizes earlier. High-cost populations become more predictable and manageable.

Most importantly, cost trend becomes something that can be influenced—rather than something that simply has to be absorbed.

This is the difference between having solutions and having a system.

What this means moving forward

Rising costs are not the root problem. They are the result of unmanaged follow-through across a fragmented system.

The organizations that are beginning to bend the cost curve are not those adding more programs. They are the ones connecting what they already have into a coordinated system that drives consistent action.

This is the shift happening now.

If you’re evaluating how this is showing up across your population, the guide above breaks down where follow-through typically breaks and how leading plans are addressing it.